- Conference Call and Webcast to Follow at 5:00 p.m. EST/2:00 p.m.
PST -
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 20, 2015--
Exelixis, Inc. (NASDAQ: EXEL) announced today that its third quarter
2015 financial results will be released on Tuesday, November 10, 2015
after the markets close. At 5:00 p.m. EST / 2:00 p.m. PST, Exelixis
management will host a conference call to discuss the results and
provide a general business update. The conference call will be
accessible via the Internet from the company’s website.
To access the webcast link, log onto www.exelixis.com
and proceed to the Event Calendar page under Investors & Media. Please
connect to the company’s website at least 15 minutes prior to the
conference call to ensure adequate time for any software download that
may be required to listen to the webcast. Alternatively, please call
(855) 793-2457 (domestic) or (631) 485-4921 (international) and provide
the conference call passcode 62011541 to join by phone.
A telephone replay will be available until 11:59 p.m. EST on November
12, 2015. Access numbers for the telephone replay are: 855-859-2056
(domestic) and 404-537-3406 (international); the passcode is 62011541. A
webcast replay will also be archived on www.exelixis.com
for one year.
About Exelixis
Exelixis, Inc. is a biopharmaceutical company committed to developing
small molecule therapies for the treatment of cancer. Exelixis is
focusing its development and commercialization efforts primarily on
cabozantinib, its wholly-owned inhibitor of multiple receptor tyrosine
kinases. Another Exelixis-discovered compound, cobimetinib, a selective
inhibitor of MEK, received its first regulatory approval in Switzerland
and is being evaluated by Roche and Genentech (a member of the Roche
Group) in a broad development program under a collaboration with
Exelixis. For more information, please visit the company's web site at www.exelixis.com.
Exelixis, the Exelixis logo, and COMETRIQ are registered U.S.
trademarks.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151020006804/en/
Source: Exelixis, Inc.
Investors Contact:
Exelixis, Inc.
Susan
Hubbard, 650-837-8194
Investor Relations and
Corporate
Communications
shubbard@exelixis.com
or
Media
Contact:
For Exelixis, Inc.
Hal Mackins,
415-994-0040
hal@torchcommunications.com